0001708138-20-000043.txt : 20200420 0001708138-20-000043.hdr.sgml : 20200420 20200420192735 ACCESSION NUMBER: 0001708138-20-000043 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200416 FILED AS OF DATE: 20200420 DATE AS OF CHANGE: 20200420 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LAROSA JOSEPH J CENTRAL INDEX KEY: 0001238303 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 20803682 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2020-04-16 0 0000872589 REGENERON PHARMACEUTICALS, INC. REGN 0001238303 LAROSA JOSEPH J 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 0 1 0 0 EVP General Counsel and Secret Common Stock 2020-04-20 4 S 0 669 567.3 D 15547 D Common Stock 2020-04-20 4 S 0 234 569.41 D 15313 D Common Stock 2020-04-20 4 S 0 125 570.27 D 15188 D Common Stock 2020-04-20 4 S 0 112 571.65 D 15076 D Common Stock 2020-04-20 4 S 0 61 572.94 D 15015 D Common Stock 2020-04-20 4 S 0 577 573.59 D 14438 D Common Stock 287 I By 401(k) Plan Non-Qualified Stock Option (right to buy) 59.2 2020-04-16 4 M 0 5000 0.0 D 2021-09-01 Common Stock 5000 29933 D Non-Qualified Stock Option (right to buy) 59.2 2020-04-17 4 M 0 6622 0.0 D 2021-09-01 Common Stock 6622 23311 D Non-Qualified Stock Option (right to buy) 59.2 2020-04-17 4 M 0 5000 0.0 D 2021-09-01 Common Stock 5000 18311 D Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Represents volume-weighted average price of sales of 669 shares of Company stock on April 20, 2020 at prices ranging from $567.00 to $567.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Represents volume-weighted average price of sales of 234 shares of Company stock on April 20, 2020 at prices ranging from $569.22 to $569.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Represents volume-weighted average price of sales of 125 shares of Company stock on April 20, 2020 at prices ranging from $570.03 to $570.50. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. Represents volume-weighted average price of sales of 577 shares of Company stock on April 20, 2020 at prices ranging from $573.31 to $573.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Form two of two /s/**Joseph J. LaRosa 2020-04-20